Pharma Journalist -

Lysogene, a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced that it has exercised its option to enter into an exclusive worldwide…
Read More...

Achilles Therapeutics plc a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced clinical manufacturing expansion in the…
Read More...

Direct Biologics, an innovative biotechnology company with a groundbreaking extracellular vesicle (EV) platform drug technology, announced that the U.S. Food and Drug Administration…
Read More...

Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health, and Ginkgo Bioworks, the leading horizontal platform for cell programming, today…
Read More...

Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform,…
Read More...

SciRhom GmbH announced that it has nominated the anti-iRhom2 antibody it will advance into clinical development. For this antibody, the company has closed an agreement with a top-tier…
Read More...

Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update…
Read More...

Telix announces a licence agreement for Lilly’s olaratumab antibody, for diagnosis and treatment of human cancers. Telix is pleased to announce that it has entered into a licence…
Read More...

Kyttaro announces that it has entered into an agreement for the worldwide exclusive license of an anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody program developed by Eli Lilly…
Read More...

Glenmark Pharmaceuticals Limited, an innovation-driven, global pharmaceutical company, announced that its subsidiary Glenmark Specialty S.A. (Glenmark) received approval from the Indian…
Read More...